Open Access Research Article Article ID: OJC-3-108

    Potential of Imiquimod and Fulvestrant against Mycobacterium tuberculosis using Molecular docking approach

    Asma Noor*, Muhammad Imran Qadir, Ardas Masood, Jawaria Khan and Sania Ahmad

    Mycobacterium Tuberculosis cause severe disease of lungs known as Tuberculosis. It is a major cause of morbidity and mortality even in the emerging countries also. However, to prepare an antibiotics drug against Mycobacterium tuberculosis is a major challenge. Two compounds Imiquimod, Fulvestrant were selected for our study which can stop action of Arbinosyl transferase enzyme of M.tuberculosis. In silico docking was carried out by using software named swissdock (http://www.swissdock.ch/). These are computer aided drug designing techniques which are helpful for this study. Both the above 2 drugs have the potential to block the activity of mutant strain of M.tuberculosis.

    Keywords: Mycobacterium tuberculosis; Imiquimod; Fulvestrant

    Published on: Jul 28, 2017 Pages: 23-25

    Full Text PDF Full Text HTML DOI: 10.17352/ojc.000008
    Get Citation Base Search Scilit OAI-PMH ResearchGate GrowKudos CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on OJC